Zura Bio Ltd ZURA
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-07-16 |
| Shares Out. | 95,000,000 |
| Website | zurabio.com/ ↗ |
| Phone | 18582470520 |
| Employees | 40 |
| Net Income | -$24.2M |
| Free Cash Flow | -$72.8M |
| Total Assets | $228.6M |
| Total Liabilities | $11.7M |
| Equity | $216.9M |
About Zura Bio Ltd
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.
Zura Bio Ltd is a publicly traded company under the ticker symbol ZURA on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
14 analysts (2026-07-01)